IntroductionIn 2017, the Centers for Disease Control and Prevention (CDC) recommended Pre-exposure prophylaxis (PrEP). PrEP is prescribed for individuals who are HIV negative, at a high risk of being exposed to HIV due to their lifestyles. PrEP is a combination of antiretroviral medications combined in a single tablet taken daily. PrEP, works to prevent the virus from establishing a permanent infection in the body PrEP involves taking an antiretroviral pill every day and seeing a healthcare provider every three months to take an HIV test and get a prescription refill (Smith et al., 2018). Studies have proved when taken as prescribed Pre-exposure prophylaxis (PrEP) PrEp has likely contributed to a substantial decline in the HIV epidemic. Purpose StatementThe purpose of this proposal is to investigate the feasibility and effectiveness of pre-exposure prophylaxis (PrEP) as a means of preventing HIV infection in high-risk populations.Part bBackground and SignificanceCurrently, over 36 million people worldwide have HIV. In 2016, there were 2.10 million new HIV infections and 1.80 million AIDS-related deaths. UNAIDS predicts this for 2016. In Sub-Saharan Africa, roughly one-quarter of the population is HIV-positive. Pre-exposure prophylaxis (PrEP), which involves daily antiviral medication, is one of the most promising HIV prevention strategies. Studies show PrEP is highly effective in preventing HIV infection in high-risk populations, including heterosexual couples with one HIV-positive partner and the other not. Many concerns remain unanswered about how to best implement PrEP programs, including who should be provided PrEP and how often. This project will examine the feasibility and effectiveness of PrEP in high-risk groups. This study’s purpose is to teach policymakers and healthcare practitioners on how to best use PrEP to prevent HIV infection. Explanation:Part aPre-exposure prophylaxis, or PrEP, is a newer intervention technique that entails taking an antiviral pill every day to prevent HIV infection. PrEP has generated a lot of attention and enthusiasm as a potential approach to drastically reduce the number of new HIV infections, but there is still a lot of doubt about how well it works and who should use it. The purpose of this proposal is to look into the feasibility and effectiveness of PrEP as a method of preventing HIV infection in high-risk populations.Part bCurrently, more than 36 M individuals global are diseased with HIV. As per the UNAIDS HIV/AIDS there were 2.10 M new HIV infections and 1.80 M AIDS-related deaths in 2016. According to UNAIDS, this will be the case in 2016. The vast majority of HIV-positive people in Sub-Saharan Africa are infected; around one-quarter of the population is infected. Pre-exposure prophylaxis (PrEP), which entails taking an antiviral pill every day, is one of the most promising techniques for preventing HIV infection. According to a number of recent studies, PrEP is highly successful at preventing HIV infection in high-risk populations, including heterosexual couples where one spouse is HIV-positive but the other isn’t. The ideal way to execute PrEP programs, including who should be offered PrEP and how often it should be taken, still has many unsolved questions.This proposal seeks to investigate the feasibility and effectiveness of PrEP as a means of preventing HIV infection in high-risk populations. The goal of this study is to provide information that can help policymakers and healthcare providers make informed decisions about how to best utilize PrEP to prevent HIV infection.Referenceshttps://jamanetwork.com/journals/jama/fullarticle/2735508Koechlin, F. M., Fonner, V. A., Dalglish, S. L., O’Reilly, K. R., Baggaley, R., Grant, R. M., … & Kennedy, C. E. (2017). Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS and Behavior, 21(5), 1325-1335.Eakle, R., Gomez, G. B., Naicker, N., Bothma, R., Mbogua, J., Cabrera Escobar, M. A., … & TAPS Demonstration Project Team. (2017). HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: results from a prospective observational demonstration project. PLoS medicine, 14(11), e1002444. Health Science Science Nursing NURSING MS 502 Share QuestionEmailCopy link Comments (0)
Recent Comments